Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 5th Preview)
-
Liquid biopsy moves beyond cancer: cfDNA epigenomics detects liver disease
Researchers published two independent advances this week that broaden the scope of liquid biopsy from oncology into chronic liver disease. Peking University teams described cf‑EpiTracing, an antibody‑based cfDNA chromatin‑state assay that infers tissue and cell‑type origins from plasma chromatin marks (Nature). Separately, Johns Hopkins investigators used genome‑wide cfDNA fragmentomics and machine learning to identify signatures of fibrosis and cirrhosis (Science Translational Medicine). Fragmentomics analyzes patterns of DNA fragmentation released by dying cells; cf‑EpiTracing profiles histone modifications on circulating fragments to map affected organs. Together these studies demonstrate noninvasive ways to detect organ injury and molecular subtypes, offering clinicalizable routes for earlier diagnosis, patient selection and monitoring in liver disease and beyond.
-
Moderna to pay up to $2.25B: LNP patent settlement ends long‑running suit
Moderna reached a landmark settlement with Arbutus Biopharma and Roivant’s Genevant unit over lipid nanoparticle (LNP) delivery patents, agreeing to an upfront cash payment and a potential total payout up to $2.25 billion. The deal grants Moderna a global non‑exclusive license for the LNP technology in infectious disease vaccines and resolves years of litigation across multiple jurisdictions. Roivant and Arbutus framed the outcome as recognition of their foundational LNP contributions; Moderna emphasized that the settlement provides certainty to focus on its pipeline. The agreement clears a major legal overhang for an mRNA leader and sets financial and licensing precedents for LNP use across vaccine and therapeutic programs.
-
FDA targets compounding of GLP‑1s: 30 warning letters hit telehealth firms
The U.S. Food and Drug Administration issued 30 warning letters to telehealth and compounding firms it says are marketing unapproved, misbranded compounded GLP‑1 products as equivalent to approved brand therapies. The agency asserted that these firms made false or misleading claims about safety and efficacy and warned of potential enforcement actions, including seizure and injunction, if violations are not corrected. FDA Commissioner Marty Makary has signaled intensified oversight of compounded obesity and diabetes drugs amid surging demand; the move underscores regulatory risk for direct‑to‑consumer telehealth models that position compounded formulations as substitutes for approved biologics.
-
Prime to test FDA flexibility: Two‑patient gene‑editing bid for rare disease
Prime Medicine reversed course and is preparing an FDA filing seeking approval of its prime‑editing therapy for a form of chronic granulomatous disease (CGD) based primarily on data from two treated patients. Company executives said recent regulatory interactions — including the agency’s willingness to consider single‑trial evidence and 'plausible mechanism' pathways — prompted the decision. The approach tests whether regulators will accept highly limited but mechanistically persuasive human data for ultra‑rare conditions. If granted, Prime’s filing would set a practical precedent for bespoke and small‑cohort gene‑editing programs where large randomized trials are infeasible.
-
Gyre acquires Cullgen: $300M deal brings targeted protein degrader engine
Gyre Therapeutics announced an all‑stock acquisition of Cullgen valued at roughly $300 million, a deal that folds Cullgen’s targeted protein degradation (TPD) discovery engine and two clinical‑stage degrader programs into Gyre’s China‑focused development and manufacturing platform. The transaction gives Gyre immediate access to an oral pan‑TRK degrader and a degrader‑antibody conjugate (DAC) capability, while reshaping the combined company’s leadership. Gyre cited strategic synergies across discovery, clinical development and China commercialization; Cullgen’s TPD platform strengthens Gyre’s pipeline diversification into degrader modalities now advancing in global pharma.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.